Table 4 Baseline charateristics in NSCLC (N = 131)
Total (%) | No Antibiotics (%) | Antibiotics (%) | p value | |
|---|---|---|---|---|
Age | ||||
< 65 | 56 (42.7) | 28 (39.4) | 28 (46.7) | 0.405 |
≥ 65 | 75 (57.3) | 43 (60.6) | 32 (53.3) | |
Sex | ||||
Male | 99 (75.6) | 54 (76.1) | 45 (75) | 0.889 |
Female | 32 (24.4) | 17 (23.9) | 15 (25) | |
ECOG | ||||
0–1 | 116 (89.9) | 66 (95.7) | 50 (83.3) | 0.02 |
2–3 | 13 (10.1) | 3 (4.3) | 10 (16.7) | |
Unkown | 2 | 2 | 0 | |
Stage | ||||
III | 4 (3.1) | 3 (4.2) | 1 (1.7) | 0.625 |
IV | 127 (96.9) | 68 (95.8) | 59 (98.3) | |
Number of metastatic organ | ||||
0 or 1 | 85 (64.9) | 47 (66.2) | 38 (63.3) | 0.732 |
≥ 2 | 46 (35.1) | 24 (33.8) | 22 (36.7) | |
Brain metastasis | ||||
No | 106 (80.9) | 57 (80.3) | 49 (81.7) | 0.841 |
Yes | 25 (19.1) | 14 (19.7) | 11 (18.3) | |
Number of treatment line | ||||
1st | 39 (29.8) | 25 (35.2) | 14 (23.3) | 0.304 |
2nd | 56 (42.7) | 29 (40.8) | 27 (45) | |
≥ 3rd | 36 (27.5) | 17 (23.9) | 19 (31.7) | |
ICI | ||||
Nivolumab | 71 (54.2) | 44 (62) | 27 (45) | 0.024 |
Pembrolizumab | 41 (31.3) | 15 (21.1) | 26 (43.3) | |
Othersa | 19 (14.5) | 12 (16.9) | 7 (11.7) | |
Treatment combination | ||||
ICI alone | 104 (79.4) | 53 (74.6) | 51 (85) | 0.117 |
ICI with ICI | 7 (5.3) | 3 (4.2) | 4 (6.7) | |
ICI with chemotherapy | 20 (15.3) | 15 (21.1) | 5 (8.3) | |
Clinical trial | ||||
Yes | 65 (49.6) | 46 (64.8) | 19 (31.7) | < 0.001 |
No | 66 (50.4) | 25 (35.2) | 41 (68.3) | |
Hisotologic subtype | ||||
Adenocarcinoma | 83 (63.4) | 46 (64.8) | 37 (61.7) | |
Squamous cell carcinoma | 44 (33.6) | 24 (33.8) | 20 (33.3) | |
Othersb | 4 (3.1) | 1 (1.4) | 3 (5) | |
PD-L1 | ||||
Negative | 14 (13.6) | 11 (20.4) | 3 (6.1) | 0.058 |
Low | 30 (29.1) | 17 (31.5) | 13 (26.5) | |
High | 59 (57.3) | 26 (48.1) | 33 (67.3) | |
Unkown | 28 | 17 | 11 | |
EGFR | ||||
Negative | 92 (88.5) | 53 (89.8) | 39 (86.7) | 0.617 |
Positive | 12 (11.5) | 6 (10.2) | 6 (13.3) | |
Unkown | 27 | 12 | 15 | |
Antibiotics type | ||||
No Antibiotics | 71 (54.2) | |||
Antibiotics | 60 (45.8) | Cephalosporins | 17 (28.3) | |
Fluoroquinolones | 16 (26.7) | |||
Beta-lactam/Betalactamase inhibitors | 9 (15) | |||
Othersc | 18 (30) | |||
Administration Route | ||||
Oral | 37 | 37 (61.7) | ||
Intravenous | 23 | 23 (38.3) | ||